News | May 03, 2025
RPG Life Sciences posts Q4 FY25 net profit at Rs. 117.35 Cr
RPG Life Sciences has reported total income of Rs. 148.15 crores during the period ended March 31, 2025
RPG Life Sciences has reported total income of Rs. 148.15 crores during the period ended March 31, 2025
The Q1 2025 also witnessed a successful launch of Allegra D
The portfolio consists of liquids and immediate release solid orals which are in the therapeutic segment to treat infections associated with UTIs
Over the last 24 years, the company's sales has grown from Rs. 478 crores to Rs. 19,022 crores
Ticagrelor tablets are indicated for to reduce the risk of cardiovascular death and myocardial infarction,
These observations are procedural in nature and none of them are related to data integrity
This recertification of Company's OECD GLP is testimony to company's unwavering commitment to maintain international quality standards at the facility
The FDA issued Form 483 with one observation related to building and facility management
Niacin is indicated to reduce elevated total cholesterol, LDL cholesterol, apolipoprotein B and triglycerides (TG)
Vimta Labs has reported total income of Rs. 96.08 crores during the period ended March 31, 2025
Subscribe To Our Newsletter & Stay Updated
